Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 26 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 11 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2017.